All In Biotech

Drug Trial Radar · NCT04982224

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

A Phase 1/2 Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Patients With MET Overexpressing Advanced Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

30

Actual

Start

Nov 9, 2021

Primary completion

Oct 15, 2025

Study completion Oct 15, 2025

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jul 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called REGN5093-M114 by itself and in combination with cemiplimab. The study is focused on advanced non-small cell lung cancer (NSCLC) that produces too much of a protein called mesenchymal epithelial transition factor (MET) on the cancer cell surface. The aim of the study is to see how safe, tolerable, and effective the study drug is. This study will include 3 study groups, or cohorts, and each group is split into 2 parts: Part 1: The main purpose of part 1 is to determine a safe dose of REGN5093-M114 (Cohorts A and B), and in combination with cemiplimab (Cohort C). Part 2: The main purpose of part 2 is to use the REGN5093-M114 dose found for each cohort in part 1 to see how well the study drug works to shrink tumors. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug * Does the study drug work to reduce or delay the progression of your cancer * How much study drug is in the blood at different times * Does the body make antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Conditions

  • Advanced NSCLC

Interventions

  • REGN5093-M114Drug

    Administered by intravenous (IV) infusion

  • CemiplimabDrug

    Administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLTs)Time frame: Up to 28 days
  2. Treatment-emergent adverse events (TEAEs)Time frame: Through study completion, an average of 2 years
  3. Serious adverse events (SAEs)Time frame: Through study completion, an average of 2 years
  4. TEAEs leading to study treatment discontinuationTime frame: Through study completion, an average of 2 years
  5. TEAEs leading to deathTime frame: Through study completion, an average of 2 years
  6. Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])Time frame: Through study completion, an average of 2 years
  7. Concentrations of REGN5093-M114 in serumTime frame: Through study completion, an average of 2 years
  8. Total monoclonal antibodies (REGN5093- M114 plus unconjugated antibody) in serumTime frame: Through study completion, an average of 2 years
  9. Concentrations of M24 in plasmaTime frame: Through study completion, an average of 2 years
  10. Concentrations of cemiplimab when given in combination with REGN5093-M114Time frame: Through study completion, an average of 2 years
  11. Objective response rate (ORR)Time frame: Through study completion, an average of 2 years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Irvine School of Medicine - Suite 400, Room 407

    Orange, California

  • University of Colorado Hospital Anshutz Outpatient Pavillion

    Denver, Colorado

  • Johns Hopkins Hospital - Clinical Study Location - Skip Viragh Outpatient Cancer Building

    Baltimore, Maryland

  • Sidney Kimmel Comprehensive Cancer Center - 4F Second Medical Building

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Hospital, Henry Ford Cancer Institute

    Detroit, Michigan

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Pittsburgh Medical Center - Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • MUSC Hollings Cancer Center

    Charleston, South Carolina

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Next Virginia

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.